Advertisement
Advertisement

Read Now: TheBodyPRO.com Covers AIDS 2014

Raltegravir Safe During Pregnancy

Summer/Fall 2010

Pregnant women with HIV can safely use raltegravir with no need for dose adjustment to account for changes in body size or blood volume, according to a study reported at ICAAC (abstract H-1668a).

Researchers looked at raltegravir pharmacokinetics in ten HIV positive women in the IMPAACT P1026s study, collecting data from the third trimester of pregnancy through six weeks after delivery. All women took the standard adult dose of 400 mg twice daily.

Raltegravir pharmacokinetic parameters varied widely among study participants, but none were significantly different for the pregnant women as a group compared with non-pregnant adults in prior studies; average raltegravir concentrations usually reached the target therapeutic level. The drug readily crossed the placenta and was detected in umbilical cord blood.

"Raltegravir exposure was not consistently altered during third trimester compared to post-partum and historical data, and the standard dose appears appropriate during pregnancy," the researchers concluded.

Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.




This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement